Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02446236 · ClinicalTrials.gov registry record · Phase 1

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

A Phase 1 study of Mantle Cell Lymphoma, sponsored by Hackensack Meridian Health.

Active
Registry status
Phase 1
Development phase
27
Enrollment target
1
Study location

NCT02446236 is a Phase 1 study of Mantle Cell Lymphoma that is active but no longer recruiting, run by Hackensack Meridian Health. The registered enrollment target is 27 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02446236, a Phase 1 study of Mantle Cell Lymphoma, is active but no longer recruiting, sponsored by Hackensack Meridian Health.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

This is a dose-escalation to determine the MTD and/or RPII for combinations of ibrutinib (PCI-32765) plus lenalidomide/rituximab in patients with relapsed/refractory mantle cell lymphoma.

Conditions Studied

Mantle Cell Lymphoma

Interventions

  • DRUG Rituximab
  • DRUG Lenalidomide
  • DRUG Ibrutinib

Study Locations (1)

New Jersey

  • The Cancer Center at Hackensack University Medical Center - Hackensack

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2015-06-18
Est. Completion 2026-07
Phase Phase 1

Sponsor

Hackensack Meridian Health

90 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02446236

The ClinicalTrials.gov registry entry for NCT02446236 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (74% lower). The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.

NCT02446236 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT02446236 about?

NCT02446236 is a clinical study titled "Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma". This is a dose-escalation to determine the MTD and/or RPII for combinations of ibrutinib (PCI-32765) plus lenalidomide/rituximab in patients with relapsed/refractory mantle cell lymphoma.

What is the current status of trial NCT02446236?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-06-18. Estimated completion is 2026-07.

What conditions does trial NCT02446236 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma.

What interventions are being tested in trial NCT02446236?

The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG), Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT02446236?

This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02446236 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.